Lilly wins oral GLP‑1 approval

The Food and Drug Administration approved Eli Lilly’s Foundayo, the oral obesity drug orforglipron, on April 1. (fda.gov) (lilly.com) Foundayo is a glucagon-like peptide-1, or GLP-1, pill, a class of medicines that helps people feel full and eat less. Lilly said it is the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. (lilly.com) (accessdata.fda.gov) The approval covers adults with obesity and adults who are overweight with at least one weight-related condition, alongside diet and physical activity. The Food and Drug Administration’s approval letter lists long-term weight reduction and weight maintenance as the indicated use. (accessdata.fda.gov) (ajmc.com) Lilly said adults taking the highest Foundayo dose lost an average of 27 pounds in the ATTAIN-1 trial. The company said the drug will be sold through LillyDirect with prices starting at $25 a month for commercially insured patients and $149 for self-pay. (lilly.com 1) (lilly.com 2) The approval also arrived unusually fast. The Food and Drug Administration said Foundayo was cleared 50 days after filing and 294 days before its January 20, 2027 user-fee deadline under the agency’s National Priority Voucher pilot. (fda.gov) At the same time, federal regulators are moving against the parallel market in compounded GLP-1 products. In February, the Food and Drug Administration said it intended to restrict active ingredients used in non-approved compounded GLP-1 drugs mass-marketed by telehealth companies and pharmacies. (fda.gov) In March, the agency said it sent 30 warning letters to telehealth companies over false and misleading claims about compounded GLP-1 products sold on their websites. Commissioner Marty Makary said the agency was entering “a new era of enforcement.” (fda.gov) The Food and Drug Administration has also told compounders that shortage-related flexibility is narrowing as national GLP-1 supply stabilizes, including for tirzepatide injection products. The agency separately warns that it cannot verify the safety, effectiveness, or quality of unapproved GLP-1 versions. (fda.gov 1) (fda.gov 2) That leaves clinics, surgery teams, and primary care practices with a longer list of brand and generic GLP-1 names to capture in medication histories. A pill that does not require injections and can be taken without meal timing rules adds one more product patients may not describe simply as “Ozempic” or “a weight-loss shot.” (accessdata.fda.gov) (lilly.com)